Cost-effectiveness of semaglutide 2.4 mg versus liraglutide 3 mg for the treatment of obesity in Greece
BackgroundObesity is a major public health issue associated with significant humanistic and economic burden. In Greece, liraglutide 3.0 mg is currently the only reimbursed pharmacotherapy for obesity, restricted to patients with morbid obesity and selected comorbidities. Semaglutide 2.4 mg has demon...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2025-10-01
|
| Серии: | Frontiers in Public Health |
| Предметы: | |
| Online-ссылка: | https://www.frontiersin.org/articles/10.3389/fpubh.2025.1690211/full |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|